


## **HEALTH SERVICES 2021**

## Fulgent Genetics Inc. Rank 2 of 79










## **HEALTH SERVICES 2021**





The relative strengths and weaknesses of Fulgent Genetics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Fulgent Genetics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 105% points. The greatest weakness of Fulgent Genetics Inc. is the variable Intangible Assets, reducing the Economic Capital Ratio by 4.2% points.

The company's Economic Capital Ratio, given in the ranking table, is 300%, being 257% points above the market average of 43%.

| Input Variable                        | Value in<br>1000 USD |
|---------------------------------------|----------------------|
| Assets, Current                       | 523,616              |
| Assets, Non-Current                   | 4,144                |
| Cost of Goods and Services Sold       | 89,807               |
| Depreciation, Depletion, Amortization | 0                    |
| General and Administrative Expense    | 15,215               |
| Goodwill Impairment Loss              | 0                    |
| Intangible Assets                     | 0                    |
| Labor Expense                         | 0                    |
| Liabilities, Current                  | 130,115              |
| Long Term Liabilities                 | 582                  |
| Operating Costs and Expenses          | 0                    |
| Other Assets                          | 132,502              |
| Other Compr. Net Income               | 292                  |
| Other Expenses                        | 76,886               |
| Other Liabilities                     | 377                  |
| Other Net Income                      | -488                 |
| Other Revenues                        | 423,238              |
| Property Plant and Equipment          | 40,199               |
| Research And Development Expense      | 11,580               |
| Selling and Marketing Expense         | 14,952               |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 700,461              |
| Liabilities              | 131,074              |
| Expenses                 | 208,440              |
| Revenues                 | 423,238              |
| Stockholders Equity      | 569,387              |
| Net Income               | 214,310              |
| Comprehensive Net Income | 214,602              |
| Economic Capital Ratio   | 300%                 |

